Top Markets
#1 Siren Siren +33.90%
#2 Wiki Cat Wiki Cat +25.38%
#3 TRIA TRIA +20.37%
#4 Ribbita by Virtuals Ribbita by Virtuals +17.09%
#5 PulseChain PulseChain +16.92%
#6 Velvet Velvet +15.56%
#7 Bitway Bitway +15.11%
#8 Nockchain Nockchain +14.64%
#9 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +14.63%
#10 KUB Coin KUB Coin +14.59%
Coin of the day
Siren Siren
設定
言語
日本
通貨
USD
テーマ
Smruthi Organics Limited Smruthi Organics Limited

Smruthi Organics Limited

SMRUTHIORG
株式のランク #30775
Smruthi Organics Ltd. primarily focuses on the production and commercialization... Smruthi Organics Ltd. primarily focuses on the production and commercialization of bulk pharmaceutical ingredients and their chemical intermediates. The company's product range includes a variety of compounds such as amlodipine besilate, amisulpride, carbidopa, ciprofloxacin, diloxanide furoate, fenofibrate, metformin hydrochloride, norfloxacin, pefloxacin, telmisartan, amlodipine base, and phthaloyl amlodipine. This enterprise was established on July 11, 1989, by Purushotham Mallayya Eaga and is based in Solapur, India.
株価
$1.36
時価総額
$15.59M
変化（1日）
0.57%
変化（1年）
1.48%
国
IN
取引 Smruthi Organics Limited (SMRUTHIORG)

カテゴリー

Healthcare
Smruthi Organics Limited（SMRUTHIORG）の収益
Aug 2026 時点の収益 TTM: 0
Smruthi Organics Limited の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Smruthi Organics Limited の収益履歴（2026 ～ 2026）
各年末の収益
年 収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差 国
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
 $2.54B -
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
 - -
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
 - -
FR
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
CORT.US
 $830.81M -
US
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI
 - -
IT